LiverMultiScan’s noninvasive MRI biomarker cT1 predicts clinical outcomes in liver disease patients, outperforming FibroScan’s transient elastography and FIB-4, with performance comparable to invasive liver biopsy. After accounting for high technical failure rates, FibroScan lost prognostic value—underscoring cT1 as a robust, noninvasive risk-stratification biomarker.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?